
CAS 1127442-87-8
:Formula:C25H19N3O3
InChI:InChI=1S/C25H19N3O3/c29-23(27-19-5-1-3-14-4-2-12-26-22(14)19)15-8-10-18(11-9-15)28-24(30)20-16-6-7-17(13-16)21(20)25(28)31/h1-12,16-17,20-21H,13H2,(H,27,29)/t16-,17+,20+,21-
InChI key:ZGSXEXBYLJIOGF-BTYSMDAFSA-N
SMILES:C1[C@@H]2C=C[C@H]1[C@H]3[C@@H]2C(=O)N(C3=O)C4=CC=C(C=C4)C(=O)NC5=CC=CC6=C5N=CC=C6
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
rel-4-[(3aR,4R,7S,7aS)-1,3,3a,4,7,7a-Hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinylbenzamide
CAS:Formula:C25H19N3O3Purity:%Color and Shape:SolidMolecular weight:409.4367exo-IWR-1
CAS:exo-IWR-1 (exo-IWR 1) is an inactive stereoisomer of Endo-IWR-1,and is a negative control of IWR-1. IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-cateninFormula:C25H19N3O3Purity:97.41%Color and Shape:SolidMolecular weight:409.44exo-IWR-1
CAS:Controlled ProductApplications exo-IWR-1 is the enantiomer of IWR-1 (I941800). exo-IWR-1 is an SAR anticancer Wnt response inhibitor. Such compounds may be used in the treatment of Wnt protein signaling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
References Lepourcelet, M., et al.: Cancer Cell, 5, 91 (2004), Barker, N., et al.: Nat. Rev. Drug Disc., 5, 997 (2006), Clevers, H., et al.: Cell, 127, 469 (2006), Jin, G., et al.: Bioorg. Med. Chem. Lett., 19, 606 (2009),Formula:C25H19N3O3Color and Shape:NeatMolecular weight:409.437exo-IWR-1
CAS:Negative control for endo-IWR-1Formula:C25H19N3O3Purity:Min. 95%Molecular weight:409.44 g/mol





